Material Detail

The study introduced a novel nanocapsule for targeted CRISPR-Cas9 delivery to the brain, specifically for glioblastoma gene therapy. The nanocapsules effectively targeted glioblastoma tissue, resulting in significant gene editing efficiency with minimal off-target effects. This innovative delivery system addresses various challenges and demonstrates safe and specific gene editing delivery for improved glioblastoma treatment, with potential applications in other brain diseases.

This will delete the comment from the database. This operation is not reversible. Are you sure you want to do it?

Thank you for reporting a broken "Go to Material" link in MERLOT to help us maintain a collection of valuable learning materials.

If you feel this material is inappropriate for the MERLOT Collection, please click SEND REPORT, and the MERLOT Team will investigate. Thank you!

You are being taken to the material on another site. This will open a new window.

Do not show me this again